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Abstract
Acute myocardial infarction (AMI) results in systolic dysfunction, myocarditis and fibrotic 
remodeling, which causes irreversible pathological remodeling of the heart. Associated cell death 
and inflammation cause cytokine release, which activates the p38 MAPK signaling pathway to 
propagate damaging signals via MAPKAP kinase 2 (MK2). Previously we showed that 
intraperitoneal injection of a cell permeable peptide inhibitor of MK2, MMI-0100, protects against 
fibrosis, apoptosis and systolic dysfunction in a mouse model of AMI induced by left-anterior 
descending coronary artery (LAD) ligation. Here we tested a new route of administration of 
MMI-0100: inhalation of nebulized peptide. When given within 30 min of AMI and daily for 2 
weeks thereafter, both inhaled and injected MMI-0100 improved cardiac function as measured by 
conscious echocardiography. Limited fibrosis was observed after 2 weeks by Massons trichrome 
staining, suggesting that MMI-0100 protects the heart prior to the formation of significant fibrosis. 
These results support a nebulized route of administration of MMI-0100 can protect the 
myocardium from ischemic damage.
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Introduction
Ischemic heart disease contributes to considerable worldwide morbidity and mortality. In the 
United States alone almost 800,000 myocardial infarctions occur per year. While 
interventional therapies such as rapid reperfusion have reduced patient death, pathological 
cardiac remodeling occurs resulting in heart failure in many patients. Current therapies to 
prevent or reverse this remodeling are lacking.
Post-MI remodeling is characterized by inflammation, hypertrophy, apoptosis and fibrosis in 
and around the area of ischemic injury. Recent studies have implicated the activation of the 
p38 MAPK pathway in the initial pathological response to injury and the remodeling process 
(Arabacilar and Marber 2015). However, it is still controversial whether p38MAPK is an 
ideal drug target for ischemic injury, as it seems to regulate both beneficial and pathological 
downstream effectors (Bassi et al. 2008). Because of these dual roles of p38 MAPK, 
downstream targets of p38 MAPK provide more attractive targets for pharmacological 
inhibition. One such downstream kinase of p38 MAPK is mitogen activated protein kinase 
activated protein kinase II (MK2). A MK2 knockout mouse model that was subjected to 
ischemia–reperfusion injury to the heart exhibited improved cardiac function, reduced 
infarct size, and reduced cardiomyocyte apoptosis compared to wild type litter-mate controls 
(Shiroto et al. 2005). However, perhaps due to the similarity between the active (ATP-
binding) site of MK2 with other kinases, specific small-molecule inhibitors have not been 
identified.
A cell-permeable peptide inhibitor of MK2, MMI-0100, is currently in clinical trials for the 
treatment of pulmonary fibrosis. We have previously demonstrated that intraperitoneal (IP) 
injection of 50 μg/kg/day MMI-0100 protects against systolic dysfunction, fibrosis and 
cardiomyocyte apoptosis in an LAD ligation model of AMI (Xu et al. 2014). In this study 
we hypothesize that inhalation of nebulized MMI-0100 will show similar protection of 
systolic dysfunction and fibrosis as we previously observed with IP injected administration 
in an LAD ligation model of AMI.
Materials and Methods
Peptide Synthesis and Delivery
The MK2 inhibitor peptide, MMI-0100 (YAR-AAARQARAKALARQLGVAA), was 
synthesized with standard Fmoc chemistry, as previously described (Ward et al. 2009). The 
peptide was prepared in PBS and delivered by IP injections (50 μg/kg/day) or by inhalation 
of nebulized particles (100 μg/kg/day). Nebulization was performed using an Aeroneb® Lab 
Nebulizer, which produces a particle size of 2.5–4 μm. Nebulized MMI-0100 peptide was 
administered in 100 μl PBS at a dose of 100 μg/kg/day for 14 days. The higher dose of 
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nebulized particles was chosen to compensate for the loss of peptide condensate in the 
tubing of the nebulizer.
Animals and Myocardial Infarction Model
C57BL/6 mice (12 week-old, male, 25–30 g) were obtained from Jackson Laboratories (Bar 
Harbor, ME) and maintained in the University of North Carolina at Chapel Hill facilities for 
at least 7 days with ad libitum access to standard rodent chow and water. Acute myocardial 
infarction was induced by permanent ligation of the left anterior descending (LAD) coronary 
artery as previously described (Maejima et al. 2013; Qian et al. 2012). Mice were 
immediately treated with lidocaine (6 mg/kg IM) and atropine (0.04–0.10 mg/kg IM) upon 
surgical closure. Lidocaine and atropine were given every 2–4 h for the first 24 h to prevent 
arrhythmias. Mice were additionally given 0.1 mg/kg buprenorphine every 12 h for the first 
48 h. Within the first hour post-MI, 50 μg/kg/day MMI-0100 peptide (or PBS control) was 
given IP or 100 μg/kg/day MMI-0100 (or PBS control) was nebulized and inhaled. 
Treatment was repeated daily for a total of 14 days.
Echocardiography
Cardiac function in mice was assessed by transthoracic, conscious echocardiography 
performed at baseline and weekly thereafter using a VisualSonics Vevo 2100 ultrasound 
biomicroscopy system (VisualSonics, Inc., Toronto, Ontario, Canada), as previously 
described (Willis et al. 2007, 2009, 2014). Briefly, Two-dimensional M-mode 
echocardiography was performed in the parasternal long-axis view at the level of the 
papillary muscle on loosely restrained mice by investigators blinded to mouse genotype 
throughout the process of collection and analysis. Posterior and anterior wall thickness was 
measured as the distance from the epicardial to the endocardial leading edge. Internal left 
ventricular diameters were also measured. Left ventricular (LV) systolic function was 
measured by ejection fraction (LV EF % = [(LV Vol; d-LV Vol; s/LV Vol; d) × 100] and 
fractional shortening (%FS = [(LVEDD − LVESD)/LVEDD] × 100). Three cardiac cycles 
were averaged from each mouse to represent a single measurement.
Histological Analysis
Mice were euthanized with isoflurane and cervical dislocation on day 14. The hearts were 
removed, fixed in fresh 4 % paraformaldehyde for 24 h, stored in 70 % EtOH and paraffin-
embedded. Fibrosis analysis Hearts were sectioned into 10 levels (3 sections per level) with 
75 μm skipped between levels and stained with Masson’s Trichrome (MT). Fibrosis was 
determined in a blinded manner using Aperio Imagescope algorithm analysis (Positive Pixel 
Count v9, Hue 0.66, Hue Width 0.4). H&E stain Three sections were taken from each heart 
starting 150 μm from the site of the ligation and stained with hematoxylin and eosin (H&E) 
using standard protocols.
Results and Discussion
In a previous study we demonstrated that injected MMI-0100 peptide exhibits 
cardioprotection in a mouse model of acute myocardial infarction (Xu et al. 2014). However, 
IP injection of a peptide therapeutic after infarct in patients is not a feasible treatment 
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option. In the present, study we tested the efficacy of an alternate mode of administration, 
inhalation of nebulized peptide, which could be quickly and easily administered to affected 
patients. Given the close relationship between the heart and lungs via pulmonary circulation, 
we hypothesized that nebulized MMI-0100 would provide the same cardioprotection that we 
previously described using injected peptide. Indeed, in this study we observed similar levels 
of EF and FS protection in both injected and inhaled MMI-0100.
Treatment of AMI with Nebulized MMI-0100 Peptide Preserves Cardiac Function In Vivo
To assess the effect of MMI-0100 on post-MI cardiac function, we investigated four 
experimental groups: (1) AMI control group (nebulized PBS, IP PBS); (2) AMI 
experimental group (nebulized MMI-0100, IP PBS); (3) AMI experimental group (nebulized 
PBS, IP MMI-0100); and (4) sham control group (nebulized MMI-0100, IP PBS). 
Treatments were given 30 min post-LAD ligation and administered daily for 2 weeks (Fig. 
1a). Baseline echocardiography was performed prior to the surgery and at 7 and 14 days 
post-MI to assess cardiac function and blindly analyzed prior to final statistical analysis (Fig. 
1b). Assessment of ejection fraction and fractional shortening (Fig. 1c) demonstrated that 
myocardial infarction induced by permanent ligation of the LAD (Group 2 LAD + PBS) 
resulted in declined systolic function compared to sham treated mice (−21.2 EF %, −32.2 FS 
%). Treatment with MMI-0100 given IP starting 30 min post-LAD ligation resulted in an 
attenuation of the systolic function loss compared to sham treated mice (Fig. 1c, −9.3 EF %, 
−16.1 FS %). Interestingly, MMI-0100 delivered by nebulization similarly attenuated the 
systolic function loss at both 7 and 14 days post-MI (Fig. 1c, −10.8 EF %, −17.9 FS %).
In addition to preserving cardiac function, MMI-0100 treatment attenuated the calculated LV 
Mass post-MI that occurs after LAD ligation (Fig. 1d). Since these measurements depend 
largely on the dilation and wall thickness, it reflects the preservation of muscle mass 
normalized to body weight (Fig. 1e), which, along with heart rate, did not significantly 
change during the 2 weeks of the study (Fig. 1f, g). Anterior wall thickness significantly 
decreased in both systole and diastole in the MI control group by 7 days and improved by 
14, reflecting the remodeling process occurring (Fig. 2a, b). Similar effects were seen in the 
posterior wall thickness in systole and diastole (Fig. 2c, d). This decrease in anterior and 
posterior wall thickness due to MI is attenuated by MMI-0100 treatment delivered IP and 
inhalationally (Fig. 2a–d). MMI-0100 treatment (IP and inhalationally delivered) similarly 
attenuate the changes in MI-induced dilation in systole (Fig. 2e) but not diastole (Fig. 2f), 
reflecting changes in LV Volumes in systole and diastole (Fig. 2g, h). Taken together, these 
studies illustrate that the dilated LV (Fig. 2e–h) characteristic of systolic dysfunction (Fig. 
1c), support the interpretation that MMI-0100 treatment attenuates MI-induced heart failure 
when delivered IP or inhalationally.
Histological Analysis of After 2 weeks of Daily MMI-0100
In our initial prior studies, we tested MMI-0100’s efficacy in a severe myocardial infarction 
model with the idea that daily MMI-0100 would only prevent fibrosis (Xu et al. 2014). To 
our surprise, however, daily MMI-0100 given IP resulted in significant functional protection, 
including prevent cardiomyocyte apoptosis (Xu et al. 2014). A drawback to using this severe 
model of MI model is that it resulted in a mortality nearing 50 %. Therefore, in the current 
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study, we used a permanent ligation model that was less severe by placing the LAD ligation 
at a lower level, resulting in depressed function but minimal fibrosis (3–4 % compared to our 
prior study of 20 %) (Xu et al. 2014).
In mice challenged with this modified LAD ligation and treated daily with vehicle control 
(LAD + PBS), we observed significantly increased collagen on Masson’s Trichrome stained 
histological sections of mouse hearts 2 weeks post-ligation. Cardiac sections were assayed 
from the site of the LAD ligation to the apex at ten equally distributed levels (3 sections at 
each level) as outlined in Fig. 3a. Sections were then stained with Masson’s tri-chrome, 
where minimal significant increases in collagen were seen (3–4 % collagen positive vs. 1 % 
sham controls) (Fig. 3b). With this minimal increase in focal fibrosis, MMI-0100 given IP or 
inhalationally did not significantly reduce the amount of total collagen (Fig. 3c, d). 
Histological analysis of H&E stained slides for inflammation did not detect any differences 
in inflammation between the LAD + PBS and LAD + MMI-0100 groups (IP and 
inhalationally delivered) at 14 days post-LAD ligation (Fig. 4a–d). This may reflect the 14 
day harvest timing, where acute inflammation would likely have visually dissipated, but may 
have contributed to the decline of cardiac function in the AMI control group at earlier time 
points. Further study is necessary to determine the contribution of inflammation in this 
model.
While in our previous study we proposed that the MMI-0100-mediated reduction in fibrosis 
could be contributing to the protection on cardiac function in LAD mice, these results 
suggest that the protection of cardiac function seen in Fig. 1 is independent of fibrosis, 
consistent with our previous studies demonstrating that MMI-0100 can prevent ischemia-
mediated apoptosis (Xu et al. 2014). Alternatively, MK2 inhibition may prevent the 
activation of cardiac stress responses mediated by MK2, as MK2 activation 
(phosphorylation) can inactivate protective heat shock proteins such as Hsp25/27, causing 
inflammation and apoptosis (Vidyasagar et al. 2012). Another possible mechanism for the 
protection afforded by MMI-0100 treatment in this model is due to a direct role of MK2 in 
cardiac contractility. Activation of p38MAPK has been implicated in depressed contractility 
due to a downregulation of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2) 
(Arabacilar and Marber 2015). However, additional research is necessary to implicate 
MMI-0100 treatment in the preservation of cardiac contractility in this manner.
The benefits of delivering MMI-0100 inhalationally could clinically be beneficial in the 
context of myocardial infarction for several reasons. First, it would allow delivery of the 
drug without having to start IV access, providing more rapid initiation of treatment since IV 
access takes time in even optimal situations and is made more difficult with patients with 
cardio-circulatory collapse. Second, it delivers the drug directly to the target organ, with the 
lungs being a direct line to the left ventricle. There are dosing issues to consider when 
delivering by nebulizer in general related to the dead space that nebulized drug can 
condensate prior to reaching the lungs, which is something we identified when designing the 
current studies. Like previous studies, we delivered the MMI-0100 IP at a dose of 50 
μg/kg/day (Vittal et al. 2013; Xu et al. 2014). However, the inhalationally delivered 
MMI-0100 dose we used was 100 μg/kg/day (in 100 μl PBS) because of the dead space 
between the nebulizer and the oropharynx. In pre-experimental trials, we found that 
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approximately 50 % of the starting nebulized material (50 μl MMI-0100 in PBS) was left in 
this dead space, therefore the delivered MMI-0100 dose in the current studies is estimated to 
be equal between the IP and nebulized daily doses (50 μg/kg/day).
Conclusion
In this study we find that an inhaled, nebulized administration of MMI-0100 protects against 
AMI-induced systolic dysfunction at 14 days. Using a less severe LAD ligation model 
compared to our previous study, we observed lower collagen deposition compared to our 
previous study and no decrease in collagen with or inhaled MMI-0100 treatment, suggesting 
that fibrosis does not play a significant role in the decline in systolic function. These 
findings support MK2 inhibition by MMI-0100 as a potential therapeutic in the treatment of 
acute myocardial infarction and provide an additional method of administration to reach the 
heart without the need for IV access. This provides a faster mode of administration to MI 
patients, when rapid treatment time after ischemic injury is of the utmost importance.
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Fig. 1. 
Assessment of systolic dysfunction by conscious echocardiography after inhalational and IP 
administration of the peptide MMI-0100 inhibitor, MMI-0100 in mice that have undergone 
AMI. a MMI-0100 was administered 30 min after LAD ligation and every 24 h thereafter 
until harvest at 14 days. b Baseline conscious echocardiography was performed prior to 
LAD ligation, as well as 7 and 14 days post-surgery to calculate. c Ejection fraction, 
calculated as (end Simpson’s diastolic volume – end Simpson’s systolic volume)/end 
Simpson’s diastolic volume × 100, fractional shortening, calculated as (LVEDD – LVESD)/
LVEDD × 100, d LV mass, e LV mass/BW, f BW, and g HR. Data represent mean ± SEM. A 
one way ANOVA was performed between all groups, followed by Holm-Sidak (vs. LAD 
Ligation + PBS control). *p <0.05 vs. LAD + PBS (baseline). **p <0.05 vs. LAD + PBS (7 
days). ¶p <0.05 vs. LAD + PBS (14 days)
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Fig. 2. 
Measurement of cardiac dimensions by conscious echocardiography. Measurements were 
taken of a AWTS, anterior wall thickness in systole, b AWTD, anterior wall thickness in 
diastole, c PWTS, posterior wall thickness in systole, d PWTD, posterior wall thickness in 
diastole, e LVESD, left ventricular end-systolic dimension, f LVEDD, left ventricular end-
diastolic dimension, g LV volume, systole and h LV volume, diastole. Data represent mean ± 
SEM. A one way ANOVA was performed between all groups, followed by Holm-Sidak (vs. 
LAD Ligation + PBS control). *p <0.05 vs. LAD + PBS (baseline). **p <0.05 vs. LAD + 
PBS (7 days). ¶p <0.05 vs. LAD + PBS (14 days)
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Fig. 3. 
Fibrosis analysis. 14 days after permanent LAD ligation and daily drug treatment hearts 
were harvested and fixed in 4 % PFA for sectioning. a 10 levels of sections were taken from 
the site of the LAD ligation to the apex of the heart. Three replicate sections were taken 
from each level and stained with Masson’s trichrome, for a total of 30 sections per heart 
analyzed. b Percent fibrosis was determined by calculating the area of collagen (blue stain) 
in 3–4 hearts for each group at 10 levels of sections (3 replicates of each level) using Aperio 
algorithm analysis. Representative images of c LAD ligation + vehicle, d LAD ligation + IP 
MMI-0100, e LAD ligation + Nebulized MMI-0100 and f Sham ligation + Nebulized 
MMI-0100. A Kruskal–Wallis one-way ANOVA was performed on the fibrosis % from 
serial sections using 3–4 hearts per group; each percent fibrosis per heart data point was 
composed of the weighted mean of 30 sections described in a above. If significance was 
reached (p <0.05), a post hoc all pairwise multiple comparison procedures (Tukey test) was 
performed between each of the groups to determine significance. *p <0.05 vs. all other 
groups. Heart image in A from: http://www.publicdomainfiles.com/show_file.php?
id=13939501819528
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Fig. 4. 
Histological analysis of H&E stained heart. Three sections were taken from each heart at the 
same level,150 μm from the site of the ligation, and analyzed morphologically for 
inflammation and other changes. a LAD ligation + vehicle, b LAD ligation + IP MMI-0100, 
c LAD ligation + Nebulized MMI-0100 and d Sham ligation + Nebulized MMI-0100. A 
one-way ANOVA was performed to assess significant differences using α = 0.05
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